KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Resmed (RMD) Tax Provisions (2016 - 2025)

Historic Tax Provisions for Resmed (RMD) over the last 17 years, with Q4 2025 value amounting to $103.6 million.

  • Resmed's Tax Provisions rose 4050.88% to $103.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $332.8 million, marking a year-over-year increase of 1625.93%. This contributed to the annual value of $276.8 million for FY2025, which is 1353.14% up from last year.
  • According to the latest figures from Q4 2025, Resmed's Tax Provisions is $103.6 million, which was up 4050.88% from $98.3 million recorded in Q3 2025.
  • In the past 5 years, Resmed's Tax Provisions registered a high of $296.5 million during Q1 2021, and its lowest value of $35.5 million during Q4 2021.
  • Moreover, its 5-year median value for Tax Provisions was $54.0 million (2021), whereas its average is $72.4 million.
  • In the last 5 years, Resmed's Tax Provisions soared by 93964.51% in 2021 and then plummeted by 8404.41% in 2022.
  • Over the past 5 years, Resmed's Tax Provisions (Quarter) stood at $35.5 million in 2021, then skyrocketed by 37.26% to $48.8 million in 2022, then increased by 3.85% to $50.7 million in 2023, then skyrocketed by 45.5% to $73.7 million in 2024, then surged by 40.51% to $103.6 million in 2025.
  • Its Tax Provisions stands at $103.6 million for Q4 2025, versus $98.3 million for Q3 2025 and $78.3 million for Q2 2025.